Cargando…

Low-Dose Cyclophosphamide Synergizes with Dendritic Cell-Based Immunotherapy in Antitumor Activity

Clinical immunotherapy trials like dendritic cell-based vaccinations are hampered by the tumor's offensive repertoire that suppresses the incoming effector cells. Regulatory T cells are instrumental in suppressing the function of cytotoxic T cells. We studied the effect of low-dose cyclophospha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Veltman, Joris D., Lambers, Margaretha E. H., van Nimwegen, Menno, de Jong, Sanne, Hendriks, Rudi W., Hoogsteden, Henk C., Aerts, Joachim G. J. V., Hegmans, Joost P. J. J.
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2874992/ https://www.ncbi.nlm.nih.gov/pubmed/20508851 http://dx.doi.org/10.1155/2010/798467

Ejemplares similares

COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function
por: Veltman, Joris D, et al.
Publicado: (2010)

Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy
por: Noordam, Lisanne, et al.
Publicado: (2018)

Tumour-derived exosomes as antigen delivery carriers in dendritic cell-based immunotherapy for malignant mesothelioma
por: Mahaweni, Niken M., et al.
Publicado: (2013)

Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma
por: Veltman, J D, et al.
Publicado: (2010)

Ratio of Intratumoral Macrophage Phenotypes Is a Prognostic Factor in Epithelioid Malignant Pleural Mesothelioma
por: Cornelissen, Robin, et al.
Publicado: (2014)

New Roads Open Up for Implementing Immunotherapy in Mesothelioma
por: Cornelissen, R., et al.
Publicado: (2012)

Granuloma Formation in Pulmonary Sarcoidosis
por: Broos, Caroline E., et al.
Publicado: (2013)

Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment
por: Heuvers, Marlies E, et al.
Publicado: (2012)

Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells
por: Kool, Mirjam, et al.
Publicado: (2008)

Involvement of Dendritic Cells and Th17 Cells in Induced Tertiary Lymphoid Structures in a Chronic Beryllium Disease Mouse Model
por: KleinJan, Alex, et al.
Publicado: (2021)

Evidence for local dendritic cell activation in pulmonary sarcoidosis
por: Berge, Bregje Ten, et al.
Publicado: (2012)

Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS
por: de Goeje, Pauline L., et al.
Publicado: (2018)

Synergistic antitumor effects of a TGFβ inhibitor and cyclophosphamide
por: Chen, Xin, et al.
Publicado: (2014)

Immunological profiling as a means to invigorate personalized cancer therapy
por: Hegmans, Joost PJJ, et al.
Publicado: (2013)

Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models
por: Rios-Doria, Jonathan, et al.
Publicado: (2015)

Molecular Iodine/Cyclophosphamide Synergism on Chemoresistant Neuroblastoma Models
por: Álvarez-León, Winniberg, et al.
Publicado: (2021)

T cell receptor repertoire characteristics both before and following immunotherapy correlate with clinical response in mesothelioma
por: Vroman, Heleen, et al.
Publicado: (2020)

Impaired survival of regulatory T cells in pulmonary sarcoidosis
por: Broos, Caroline E., et al.
Publicado: (2015)

Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model
por: Lau, Sai Ping, et al.
Publicado: (2020)

Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses
por: Chen, Xi, et al.
Publicado: (2020)

Improving lung cancer survival; time to move on
por: Heuvers, Marlies E, et al.
Publicado: (2012)

Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy
por: van Gulijk, Mandy, et al.
Publicado: (2018)

Cyclophosphamide loaded thermo-responsive hydrogel system synergize with a hydrogel cancer vaccine to amplify cancer immunotherapy in a prime-boost manner
por: Yang, Fan, et al.
Publicado: (2021)

Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy
por: Van Acker, Heleen H, et al.
Publicado: (2015)

Biomaterial-based platforms for in situ dendritic cell programming and their use in antitumor immunotherapy
por: Calmeiro, João, et al.
Publicado: (2019)

Immune modulating effects of cyclophosphamide and treatment with tumor lysate/CpG synergize to eliminate murine neuroblastoma
por: Gershan, Jill A., et al.
Publicado: (2015)

Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901
por: Walter, Steffen, et al.
Publicado: (2013)

The Mucosal Adjuvant Cholera Toxin B Instructs Non-Mucosal Dendritic Cells to Promote IgA Production Via Retinoic Acid and TGF-β
por: Gloudemans, Anouk K., et al.
Publicado: (2013)

Small Particles, Big Effects: The Interplay Between Exosomes and Dendritic Cells in Antitumor Immunity and Immunotherapy
por: Benites, Bruno Deltreggia, et al.
Publicado: (2019)

Dendritic Cell Subsets in Asthma: Impaired Tolerance or Exaggerated Inflammation?
por: Vroman, Heleen, et al.
Publicado: (2017)

The Future of Glioblastoma Therapy: Synergism of Standard of Care and Immunotherapy
por: Patel, Mira A., et al.
Publicado: (2014)

Targeting tumor-associated macrophages to synergize tumor immunotherapy
por: Xiang, Xiaonan, et al.
Publicado: (2021)

Synergizing radiotherapy and immunotherapy: Current challenges and strategies for optimization
por: Rajeev-Kumar, Greeshma, et al.
Publicado: (2022)

Intratumoral Lentivector-Mediated TGF-β1 Gene Downregulation As a Potent Strategy for Enhancing the Antitumor Effect of Therapy Composed of Cyclophosphamide and Dendritic Cells
por: Rossowska, Joanna, et al.
Publicado: (2017)

Current State of Dendritic Cell-Based Immunotherapy: Opportunities for in vitro Antigen Loading of Different DC Subsets?
por: Huber, Anne, et al.
Publicado: (2018)

Targeting thymidine phosphorylase alleviates resistance to dendritic cell immunotherapy in colorectal cancer and promotes antitumor immunity
por: Paladhi, Ankush, et al.
Publicado: (2022)

Activation of the D prostanoid 1 receptor suppresses asthma by modulation of lung dendritic cell function and induction of regulatory T cells
por: Hammad, Hamida, et al.
Publicado: (2007)

Ganetespib synergizes with cyclophosphamide to improve survival of mice with autochthonous tumors in a mutant p53-dependent manner
por: Alexandrova, Evguenia M, et al.
Publicado: (2017)

Short-Term Fasting Synergizes with Solid Cancer Therapy by Boosting Antitumor Immunity
por: de Gruil, Nadia, et al.
Publicado: (2022)

Immunotherapy Plus Radiotherapy for the Treatment of Sarcomas: Is There a Potential for Synergism?
por: Wang, Jiaqiang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_41nvqd9ii9jdlv4epq2978p9dt